DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication
Artículo científico (JournalArticle)
New and potential strategies for the treatment of PMM2-CDG
Background
Mutations in the PMM2 gene cause phosphomannomutase 2 deficiency (PMM2; MIM# 212065), which manifests as a congenital disorder of glycosylation (PMM2-CDG). Mutant PMM2 leads to the reduced conversion of Man-6-P to Man-1-P, which results in low concentrations of guanosine 5′-diphospho-D-mannose, a nucleotide-activated sugar essential for the construction of protein oligosaccharide chains. To date the only therapeutic options are preventive and symptomatic.
Scope of review
This review covers the latest advances in the search for a treatment for PMM2-CDG.
Major conclusions
Treatments based on increasing Man-1-P levels have been proposed, along with the administration of different mannose derivates, employing enzyme inhibitors or repurposed drugs to increase the synthesis of GDP-Man. A single repurposed drug that might alleviate a severe neurological symptom associated with the disorder is now in clinical use. Proof of concept also exists regarding the use of pharmacological chaperones and/or proteostatic regulators to increase the concentration of hypomorphic PMM2 mutant proteins.
General significance
The ongoing challenges facing the discovery of drugs to treat this orphan disease are discussed., The authors are grateful to the Spanish families affected by PMM2-CDG who actively participated in this work. Financial support was provided by grant PI19/01155, PI17/00101, B2017/BMD-3721, the Fundación Isabel Gemio/Fundación La Caixa (LCF/PR/PR16/11110018), and the European Regional Development Fund. MS research is supported by the Generalitat de Catalunya (PERIS SLT008/18/00194., Peer reviewed